- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02471638
DETOUR I Clinical Study
June 24, 2019 updated by: PQ Bypass, Inc.
PQ Bypass Systems for Femoropopliteal Bypass II (PQB 4 FP II)
To assess the safety and performance of the PQ Bypass System to access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Prospective, single-arm, multi-center, international, non-randomized, pre-market, safety and effectiveness clinical investigation evaluating the PQ Bypass Systems to access, deliver guidewires and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.
Study Type
Interventional
Enrollment (Actual)
78
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Santiago, Chile
- Universidad Catolica de Chile
-
-
-
-
-
Leipzig, Germany, 04103
- University of Leipzig Medical Centre
-
-
-
-
-
Milan, Italy, 20132
- Ospedale San Raffaele
-
-
-
-
-
Riga, Latvia, LV-1002
- Stradins University Hospital
-
-
-
-
-
Auckland, New Zealand, 1023
- Vascular Service
-
-
-
-
-
Gdańsk, Poland
- Gdansk Medical University
-
Poznan, Poland, 61-848
- Poznan University of Medical Sciences
-
Warsaw, Poland
- Institute of Haematology Medicine Indira Gandhi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 88 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to provide informed consent
- Age 18 or older
- Rutherford Classification of 3-5
- Patent iliac and femoral arteries/veins and access vessels, of sufficient size and morphology (including tortuosity), to allow endovascular access with 8 Fr. introducer sheath
Femoro-popliteal lesions ≥10 cm in length considered to be:
- Chronic total occlusion (100% stenosis)
- Diffuse stenosis (>50% stenosis) with moderate to heavy calcification
- In-stent restenosis (>50% stenosis)
- Proximal and distal target vessels are 5.4-7.0 mm in diameter
- Orifice and proximal 1 cm of SFA is patent
- Patent popliteal artery 3 cm proximal to tibial plateau
- At least 1 patent tibial artery to the foot
- Patent femoral vein ≥ 10 mm in diameter or duplicate femoral vein
- Subject has > one year life expectancy
Exclusion Criteria:
- Bypass length required > 30 cm
- History of deep vein thrombosis
- Has a known hypersensitivities, allergies or contraindications to: nitinol, PTFE; aspirin, heparin, antiplatelet, anticoagulant or thrombolytic therapy; or anticoagulation or contrast media that is not amenable to pre-treatment;
- Has a known history of intracranial bleeding or aneurysm, myocardial infarction or stroke within the last 12 months
- Pregnant or nursing
- Untreated flow-limiting aortoiliac occlusive disease
- Has renal failure (eGFR < 30mL/min)
- Major distal amputation (above the transmetatarsal) in the study or non-study limb
- Patient has had a revascularization procedure on the target limb within 30 days
- Patient has a planned amputation of the target limb
- Previous bypass surgery on the target limb
- Patient is participating in another clinical study for which follow-up is currently on going.
- Patient has a condition that in the view of the investigator precludes participation in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm study
PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
|
To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Performance Endpoint (Rate of primary patency)
Time Frame: 6 months
|
Rate of primary patency.
Primary patency defined as: no evidence of clinically significant stenosis (≥50%) within the stent graft or immediately above or below the treated arterial segment based on duplex ultrasound (systolic velocity ratio of >2.5).
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Schneider PA, Krievins DK, Halena G, Schmidt A, Lyden S, Lee V, Hu M, Adelman M. Venous outcomes at 1 year after using the femoral vein as a conduit for passage of percutaneous femoropopliteal bypass. J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1266-1272.e3. doi: 10.1016/j.jvsv.2020.12.080. Epub 2021 Jan 8.
- Krievins DK, Halena G, Scheinert D, Savlovskis J, Szopinski P, Kramer A, Ouriel K, Nair K, Holden A, Schmidt A. One-year results from the DETOUR I trial of the PQ Bypass DETOUR System for percutaneous femoropopliteal bypass. J Vasc Surg. 2020 Nov;72(5):1648-1658.e2. doi: 10.1016/j.jvs.2020.02.043. Epub 2020 Apr 8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
September 1, 2018
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
June 11, 2015
First Submitted That Met QC Criteria
June 12, 2015
First Posted (Estimate)
June 15, 2015
Study Record Updates
Last Update Posted (Actual)
June 26, 2019
Last Update Submitted That Met QC Criteria
June 24, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STP 115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on PQ Bypass System for Femoropopliteal Bypass
-
EndologixActive, not recruiting
-
PQ Bypass, Inc.Active, not recruiting
-
University Hospital, BordeauxMinistry of Health, FranceCompletedDiabetes | Arteritis
-
EndologixCompletedPeripheral Arterial DiseaseNew Zealand
-
St. Antonius HospitalUMC Utrecht; Albert Schweitzer Hospital; Amphia HospitalUnknownAtherosclerosis | Peripheral Arterial Occlusive DiseaseNetherlands
-
EndologixPQ Bypass, Inc.; SyntactxActive, not recruiting
-
Augusta UniversityRecruitingCongenital Heart DiseaseUnited States
-
University Hospital, AngersUnknownCoronary Artery Disease | Cardiopulmonary BypassFrance